Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peking Univ. FGFR4 compound 30
- Development stage
- Preclinical
- Lead developer
- Peking University
01
Overview
Peking Univ. FGFR4 compound 30: sourced facts only. name: "Representative compounds 24 and 30 exhibited potent FGFR4 inhibition and high selectivity among kinases." [PMID:35549181]; target: "Representative compounds 24 and 30 exhibited potent FGFR4 inhibition and high selectivity among kinases." [PMID:35549181]; developer: "State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen 518055, China." [PMID:35549181]; stage: "Moreover, compound 30 exhibited significant in vivo antitumor activity in a mouse HuH-7 xenograft model." [PMID:35549181]
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on Peking Univ. FGFR4 compound 30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peking Univ. FGFR4 compound 30.